Investor Presentaiton slide image

Investor Presentaiton

Research framework in action: anti-CCR8 antibody depletes T regulatory cells (Tregs) with combination potential Transformational potential First-in-class, Treg-depleting monoclonal antibody (mAb) with broad combo potential across multiple tumor types. Causal human biology Clinical trial translational data demonstrate CCR8+ regulatory T cells (T regs) are a major barrier to effective immune response to anti-PD1 therapy in multiple cancer types. Matching modality to mechanism BMS-986340 is an anti-CCR8 IgG1 biologic with enhanced non-fucosylated (NF) Fc that binds CCR8 and potently depletes T regs while sparing effector CD8 T cells. Path to clinical proof-of-concept Depletion of CCR8+ Tregs in the tumor after 2 cycles Reduced ratio CCR8 Treg to CD8+ Teff in the tumor 1.5 Anti-PD1 mAb CCR8 Suppressed anti-tumor Tumor cells survive response Activated CCR8+ Treg Ill Bristol Myers Squibb™ Т Suppressed CD8 T cell * Treatment Screening CCR8:CD8 ratio 0.5- 1.0. 0.0 Screening C2D5 Not for Product Promotional Use 26
View entire presentation